A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG
- PMID: 20141344
- DOI: 10.3109/14017430903531008
A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG
Abstract
Objective: Adverse outcome after CABG is closely related to postoperative heart failure precipitated by ischemia and myocardial infarction. Restrictive use of inotropes is therefore desirable. Patients with preoperative left ventricular dysfunction are a high-risk group in this respect. To reduce myocardial oxygen expenditure we evolved a metabolic strategy for perioperative care.
Design: Observational study on 104 consecutive patients with severe left ventricular dysfunction undergoing CABG. The metabolic strategy implied physiological measures to minimize myocardial oxygen expenditure including restrictive use of inotropes and specific measures such as extended CPB and metabolic support to facilitate myocardial recovery. Hemodynamic state was primarily assessed by mixed venous oxygen saturation (SvO(2)). Follow-up averaged 9.7+/-1.4 years.
Results: LVEF was 0.30+/-0.05 (range 0.20-0.37) and 3.5+/-1.3 vessels were bypassed. Inotropes were used in 6.7% for weaning from CPB. Increase of s-creatinine by > or =50% compared to preoperative values was observed in 2.9%. Logistic EuroSCORE was 8.3% whereas observed 30-day mortality was 1.0%. Crude 5-year survival was 89.4%.
Conclusions: The metabolic strategy allowed restrictive use of inotropes and was associated with encouraging long-term survival. Renal function was well preserved suggesting that SvO(2) served as an adequate marker of circulation. Randomized trials with metabolic support are warranted.
Comment in
-
Metabolic therapy in cardiac surgery--"Optimizing the engine's fuel supply and more...".Scand Cardiovasc J. 2010 Feb;44(1):4-8. doi: 10.3109/14017430903469928. Scand Cardiovasc J. 2010. PMID: 20141343 No abstract available.
Similar articles
-
Metabolic therapy in cardiac surgery--"Optimizing the engine's fuel supply and more...".Scand Cardiovasc J. 2010 Feb;44(1):4-8. doi: 10.3109/14017430903469928. Scand Cardiovasc J. 2010. PMID: 20141343 No abstract available.
-
Long-term outcome of coronary artery bypass grafting in patients with left ventricular dysfunction.Ann Thorac Surg. 2009 May;87(5):1401-7. doi: 10.1016/j.athoracsur.2009.02.062. Ann Thorac Surg. 2009. PMID: 19379873
-
GLUTAMICS--a randomized clinical trial on glutamate infusion in 861 patients undergoing surgery for acute coronary syndrome.J Thorac Cardiovasc Surg. 2012 Oct;144(4):922-930.e7. doi: 10.1016/j.jtcvs.2012.05.066. Epub 2012 Jun 19. J Thorac Cardiovasc Surg. 2012. PMID: 22721612 Clinical Trial.
-
The world post STICH: is this a "Game Changer?" A surgeon's perspective--revascularization is still the treatment of choice.Prog Cardiovasc Dis. 2013 Mar-Apr;55(5):470-5. doi: 10.1016/j.pcad.2012.10.013. Prog Cardiovasc Dis. 2013. PMID: 23518374 Review.
-
Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.J Am Coll Cardiol. 2003 Apr 16;41(8):1404-7. doi: 10.1016/s0735-1097(03)00164-5. J Am Coll Cardiol. 2003. PMID: 12706939 Review.
Cited by
-
Central venous oxygen saturation during cardiopulmonary bypass predicts 3-year survival.Interact Cardiovasc Thorac Surg. 2013 Jan;16(1):21-6. doi: 10.1093/icvts/ivs363. Epub 2012 Oct 12. Interact Cardiovasc Thorac Surg. 2013. PMID: 23065747 Free PMC article.
-
Artificial hyperventilation normalizes haemodynamics and arterial oxygen content in hypoxic rats.Anaesthesiol Intensive Ther. 2021;53(3):223-231. doi: 10.5114/ait.2021.106562. Anaesthesiol Intensive Ther. 2021. PMID: 34284554 Free PMC article.
-
The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.J Transl Med. 2020 May 11;18(1):193. doi: 10.1186/s12967-020-02351-7. J Transl Med. 2020. PMID: 32393387 Free PMC article. Clinical Trial.
-
Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.PLoS Med. 2022 May 9;19(5):e1003997. doi: 10.1371/journal.pmed.1003997. eCollection 2022 May. PLoS Med. 2022. PMID: 35533197 Free PMC article. Clinical Trial.
-
Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study.Perioper Med (Lond). 2021 Jul 13;10(1):21. doi: 10.1186/s13741-021-00194-4. Perioper Med (Lond). 2021. PMID: 34253255 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical